Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes.
作者信息
Kumar A, Alfahad Q, Mitra A, Elsherbiny S, Lip P L
机构信息
Birmingham and Midland Eye Centre, City Hospital, Birmingham, UK.
出版信息
Eye (Lond). 2016 May;30(5):763-4. doi: 10.1038/eye.2015.281. Epub 2016 Jan 22.
Abstract
摘要
相似文献
1
Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes.
Eye (Lond). 2016 May;30(5):763-4. doi: 10.1038/eye.2015.281. Epub 2016 Jan 22.
2
Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
Eye (Lond). 2017 Apr;31(4):650-656. doi: 10.1038/eye.2016.301. Epub 2017 Jan 20.
3
The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN) in diabetic macular oedema in a multi-ethnic inner-city population.
Eur J Ophthalmol. 2021 Mar;31(2):620-629. doi: 10.1177/1120672119898414. Epub 2020 Jan 6.
4
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
BMC Ophthalmol. 2018 Feb 27;18(1):62. doi: 10.1186/s12886-018-0726-1.
5
Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.
Curr Med Res Opin. 2017 Oct;33(sup2):33-43. doi: 10.1080/03007995.2017.1366662. Epub 2017 Sep 7.
6
Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Curr Med Res Opin. 2019 Jul;35(7):1165-1176. doi: 10.1080/03007995.2018.1560779. Epub 2019 Jan 17.
7
[Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
J Fr Ophtalmol. 2015 Feb;38(2):159-67. doi: 10.1016/j.jfo.2014.09.007. Epub 2015 Jan 16.
8
Fluocinolone acetonide for the treatment of diabetic macular edema.
Expert Opin Pharmacother. 2017 Oct;18(14):1507-1516. doi: 10.1080/14656566.2017.1363182. Epub 2017 Aug 9.
9
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN) for the Treatment of Retinal Conditions. A Review of Clinical Studies.
Drug Des Devel Ther. 2023 Mar 30;17:961-975. doi: 10.2147/DDDT.S403259. eCollection 2023.
10
Update of intravitreal steroids for the treatment of diabetic macular edema.
Ophthalmic Res. 2014;52(2):89-96. doi: 10.1159/000362764. Epub 2014 Aug 29.
引用本文的文献
1
Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases.
Biomed Microdevices. 2019 May 18;21(2):47. doi: 10.1007/s10544-019-0389-6.
2
Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review.
Ophthalmol Ther. 2018 Dec;7(2):293-305. doi: 10.1007/s40123-018-0145-7. Epub 2018 Sep 18.
3
Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN): A Review in Diabetic Macular Edema.
Drugs. 2017 Apr;77(5):575-583. doi: 10.1007/s40265-017-0722-4.
4
Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
Eye (Lond). 2017 Apr;31(4):650-656. doi: 10.1038/eye.2016.301. Epub 2017 Jan 20.
5
Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
Eye (Lond). 2017 May;31(5):684-690. doi: 10.1038/eye.2016.303. Epub 2017 Jan 13.
本文引用的文献
1
Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.
Retina. 2011 May;31(5):915-23. doi: 10.1097/IAE.0b013e318206d18c.
2
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
Invest Ophthalmol Vis Sci. 2011 Jun 28;52(7):4605-9. doi: 10.1167/iovs.10-6387.
3
Vitreous VEGF clearance is increased after vitrectomy.
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2135-8. doi: 10.1167/iovs.09-3582. Epub 2009 Dec 17.
4
Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes.
Invest Ophthalmol Vis Sci. 2008 May;49(5):2030-8. doi: 10.1167/iovs.07-0273.
5
Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema.
Retina. 2008 Mar;28(3):420-6. doi: 10.1097/IAE.0b013e318159e7d2.
Zotero 插件